Protalix BioTherapeutics Inc

Type: Company
Name: Protalix BioTherapeutics Inc (Protalix Biotherapeutics Inc)
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Array Biopharma Announces Binimetinib Continues to Advance in Clinical Development; Protalix Announces Data on Oral antiTNF

Below is a look at some of the headlines for companies that made news in the healthcare sector on April 23, 2014.Following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, ... [Published BioMedReports - 11 hours ago]
First reported 23 hours ago - Updated 20 hours ago - 3 reports

Protalix Biotherapeutics, Inc. Announces Data On Oral Antitnf To Be Presented At Meeting

(GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that preclinical data on oral antiTNF (PRX-106) was accepted for presentation at the Digestive Disease Week (DDW) Annual Meeting being held May 3-6 in Chicago, ... [Published BioSpace - 20 hours ago]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Research Frontiers Downgraded by Zacks to “Sell” (REFR)

Zacks cut shares of Research Frontiers (NASDAQ:REFR) from a hold rating to a sell rating in a research note issued to investors on Wednesday, Analyst Ratings Net reports.Zacks has also taken action a number of other stocks recently. The firm upgraded ... [Published Mideast Time - Apr 10 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Federal Home Loan Mortgage Corp Rating Lowered to Sell at Zacks (FMCC)

Tweet[embedded content]Zacks downgraded shares of Federal Home Loan Mortgage Corp (NASDAQ:FMCC) from a hold rating to a sell rating in a research note released on Wednesday morning, StockRatingsNetwork reports.Zacks has also updated their ratings on a ... [Published Mideast Time - Apr 10 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Sandvik AB Upgraded to Hold at Zacks (SDVKY)

Tweet[embedded content]Zacks upgraded shares of Sandvik AB (NASDAQ:SDVKY) from a sell rating to a hold rating in a research note issued to investors on Wednesday, American Banking & Market News reports.Zacks has also modified their ratings on a number ... [Published Mideast Time - Apr 10 2014]
First reported Apr 09 2014 - Updated Apr 10 2014 - 2 reports

Protalix BioTherapeutics Short Interest Up 2.8% in March (PLX)

Protalix BioTherapeutics (NYSE:PLX) was the recipient of a large growth in short interest in January. As of March 31st, there was short interest totalling 5,892,915 shares, a growth of 2.8% from the March 14th total of 5,734,936 shares, ARN reports. Currently, ... [Published American Banking News - Apr 10 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

PROTALIX BIOTHERAPEUTICS : Apple Orthodontix Frisco TX Orthodontist David Blackburn Earns ABO Certification

/24-7PressRelease/ -- David Blackburn , DMD, MSD is now a Board Certified orthodontic specialist. Only about 20% of all orthodontists have completed this ABO certification.Dr. Blackburn completed his DMD and MS in Orthodontics at Boston University School ... [Published 4 Traders - Apr 04 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Protalix BioTherapeutics Sees Large Decrease in Short Interest (PLX)

Protalix BioTherapeutics (NYSE:PLX) was the recipient of a significant decrease in short interest during the month of January. As of March 14th, there was short interest totalling 5,734,936 shares, a decrease of 0.5% from the February 28th total of 5,763,248 ... [Published American Banking News - Mar 27 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Protalix BioTherapeutics Up 5.1%, Shares Break Through Resistance (PLX)

Protalix BioTherapeutics (AMEX:PLX) is one of today's best performing low-priced stocks, up 5.1% to $4.76 on 1.1x average daily volume. Protalix BioTherapeutics has traded 246,000 shares thus far today, vs. average volume of 232,000 shares per day. ... [Published Individual.com - Mar 25 2014]
First reported Mar 23 2014 - Updated Mar 23 2014 - 2 reports

Medigus gets FDA nod for upgraded MUSE system

The procedure currently targets GERD patients.Medigus Ltd. (TASE:MDGS) Ltd. (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and procedures, announced today that the US Food and Drug Administration (FDA) has granted ... [Published Globes - Mar 23 2014]
First reported Mar 18 2014 - Updated Mar 19 2014 - 2 reports

Goldman Sachs also upgrades Teva

Goldman Sachs has made the same upgrade as Morgan Stanley and JPMorgan.Goldman Sachs has raised its recommendation for (NYSE: TEVA; TASE: TEVA) from "Sell", published in July 2013, to "Neutral", following the same upgrades by Morgan Stanley and JPMorgan. ... [Published Globes - Mar 19 2014]
First reported Mar 16 2014 - Updated Mar 16 2014 - 2 reports

Protalix-Pfizer collaboration disappoints [Globes, Tel Aviv, Israel :: ]

March 17--Protalix Biotherapeutics Inc. (NYSE MKT:PLX; TASE: PLX) is not yet seeing any substantial revenue flow from its agreement with Pfizer Inc. (NYSE: PFE; LSE: PFZ) to distribute the company's treatment for Gaucher's disease, Elelyso (also marketed ... [Published BusinessWeek - Mar 16 2014]

Quotes

...Units and Director of the Department of Medicine at Hebrew University-Hadassah Medical Center in Jerusalem, Israel, will present a poster titled: "A novel method for anti-TNF based-oral immunotherapy: Oral administration of a plant cell-expressed recombinant anti-TNF fusion protein for treating Crohn's disease." The poster which was accepted as late breaking research, will be presented on Tuesday, May 6 from 8:00 AM to 5:00 PM, Central Daylight Time, in the in...
Boston, MA -- (SBWIRE) -- 04/16/2014 -- Global Markets Direct's, "Rheumatoid ', provides an overview of the Rheumatoid Arthritis's therapeutic pipeline."
Robby Goldenberg, Senior Vice President and Head of the Trading and Derivatives Department remarked: "The launch of the TA Tech-Elite index is yet another measure undertaken by TASE to broaden the spectrum of financial products it offers the public, in accordance with market needs. The new index is expected to focus attention on large technology and biomed companies, render the listing of high tech companies on TASE more compelling and improve the liquidity of high tech shares."
...It's a testament to his pursuit of continued proficiency and excellence," commented CEO Chad Packard , "and just one more example of Apple's ongoing commitment to provide the highest quality orthodontic care to all north Texans."

More Content

All (49) | News (38) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (2) | Press Releases (7)
sort by: Date | Relevance
Array Biopharma Announces Binimetinib Continues... [Published BioMedReports - 11 hours ago]
Protalix Biotherapeutics, Inc. Announces Data O... [Published BioSpace - 20 hours ago]
Protalix Announces Data on Oral antiTNF to be P... [Published Noodls - 22 hours ago]
Protalix Announces Data on Oral antiTNF to be P... [Published GlobeNewswire: Acquisitions News - 23 hours ago]
Protalix Announces Data on Oral antiTNF to be P... [Published Morningstar.com - 23 hours ago]
Rheumatoid Arthritis - Pipeline Review, H1 2014... [Published Digital Journal - Apr 16 2014]
Research Frontiers Downgraded by Zacks to “Sell... [Published Mideast Time - Apr 10 2014]
Federal Home Loan Mortgage Corp Rating Lowered ... [Published Mideast Time - Apr 10 2014]
Ignyta Receives New Coverage from Analysts at Z... [Published Mideast Time - Apr 10 2014]
Central Valley Community Bancorp Downgraded to ... [Published Mideast Time - Apr 10 2014]
Sandvik AB Upgraded to Hold at Zacks (SDVKY) [Published Mideast Time - Apr 10 2014]
Protalix BioTherapeutics Short Interest Up 2.8%... [Published American Banking News - Apr 10 2014]
Electrolux AB Upgraded by Zacks to “Hold” (ELUXY) [Published Mideast Time - Apr 09 2014]
Protalix BioTherapeutics Lowered to “Underperfo... [Published American Banking News - Apr 09 2014]
TASE Implements R&D Committee Recommendations: ... [Published FinanzNachrichten.de - Apr 07 2014]
PROTALIX BIOTHERAPEUTICS : Apple Orthodontix Fr... [Published 4 Traders - Apr 04 2014]
Teva rival Mapi-Pharma files for $49m Nasdaq IPO [Published Globes - Mar 27 2014]
Protalix BioTherapeutics Sees Large Decrease in... [Published American Banking News - Mar 27 2014]
Mazor's robot used in first brain procedure [Published Globes - Mar 26 2014]
Protalix BioTherapeutics Up 5.1%, Shares Break ... [Published Individual.com - Mar 25 2014]
Brainsway predicts strong growth [Published Globes - Mar 25 2014]
Medigus gets FDA nod for upgraded MUSE system [Published Globes - Mar 23 2014]
Kamada defers trial results release [Published Globes - Mar 23 2014]
C'tee seeks to cut top-up health insurance cost [Published Globes - Mar 20 2014]
Goldman Sachs also upgrades Teva [Published Globes - Mar 19 2014]
AB Dental signs Taiwan distribution deal [Published Globes - Mar 18 2014]
Telehealth co Tyto Care raises $4m [Published Globes - Mar 18 2014]
Phoenix invests NIS 10m in Bio-Light [Published Globes - Mar 18 2014]
Novartis reportedly in talks to buy Gamida-Cell [Published Globes - Mar 18 2014]
Shekel-dollar rate near 3-year low [Published Globes - Mar 18 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Update on Protalix [Published Chimera Research Group - Proceed With Confidence - Feb 12 2014]
On Wednesday, Protalix (PLX) will present data from their phase I clinical trial of oral glucocerebrosidase (GCD), or Oral GCD (PRX-112), in patients with Gaucher disease. The presentation will be. The post Update on Protalix appeared first on Chimera ...
ClickSoftware Advances on New Clients: Israel O... [Published Bloomberg via Google News - Feb 09 2014]
ClickSoftware Advances on New Clients: Israel Overnight Bloomberg The Bloomberg Israel-US Equity Index of the largest Israeli companies traded in New York added 0.3 percent, led by Protalix BioTherapeutics Inc. SodaStream International Ltd., the ...
1

Press Releases

sort by: Date | Relevance
Protalix Announces Data on Oral antiTNF to be P... [Published GlobeNewswire: Acquisitions News - 23 hours ago]
Protalix BioTherapeutics' Technology Transfer A... [Published GlobeNewswire: Acquisitions News - Feb 06 2014]
Protalix Announces Successful Manufacturing Fac... [Published GlobeNewswire: Acquisitions News - Jan 23 2014]
Protalix BioTherapeutics Provides Full-Year 201... [Published GlobeNewswire: Acquisitions News - Jan 13 2014]
Protalix BioTherapeutics to Present at the 32nd... [Published GlobeNewswire: Acquisitions News - Jan 07 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.